Xenon anesthesia: shedding light on brain dynamics and clinical niches

Xenon is reemerging as a clinically attractive inhalational anesthetic because it combines rapid kinetics and cardiovascular stability with mechanism features that differ from GABAergic agents. Simultaneously, new membrane-biophysics and systems-neuroscience data are reshaping how models in anesthetic state transitions worked, which expands the future of how anesthetic agents are used.

Contemporary work strengthens the view that xenon acts primarily via noncompetitive NMDA receptor inhibition, with additional effects on excitability-related ion channels. Whole-cortex modeling and high-density electroencephalogram studies link xenon sedation to reduced long-range coupling, slowed alpha peak frequency, increased damping of alpha-band dynamics, and a shift toward more stable population dynamics that track response better than gas concentration. Despite this, xenon's studies do not show a consistent reduction in postoperative neurocognitive disorders. However, xenon has been shown to accelerate early recovery anesthesia times.

Though definitive outcome benefits remain unproven, xenon's value may represent a reemergent inhalational drug as the environmental carbon dioxide footprint is very attractive. Besides, the rapid recovery of xenon's general anesthesia, is also a distinct, quantifiable systems-level physiology that can guide depth monitoring and motivate targeted trials, improving the design and protocol of the studies in high-risk neurocognitive and brain-injury settings.